Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Bisphosphonate Drug Holiday & Hip Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  November 21, 2017

New research found women on bisphosphonate therapy who take a drug holiday experience a higher rate of hip fracture…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesdrug holidayFractureshiphip fracturehip fracture riskOsteoporosisosteoporosis treatments

Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids

Reuters Staff  |  November 8, 2017

NEW YORK (Reuters Health)—Early oral bisphosphonate use is associated with a lower risk of fractures among oral-glucocorticoid users, researchers from Canada report. Bisphosphonates are commonly used for glucocorticoid-induced osteoporosis, but their efficacy has been established only in primary osteoporosis, where the mechanism of action of bone loss differs from that seen with glucocorticoid use. Dr….

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesCanada reportearly oral bisphosphonate usefracture riskFracturesGlucocorticoid-Induced Osteoporosisoral-glucocorticoid usersOsteoporosis

Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

Michele B. Kaufman, PharmD, BCGP  |  September 27, 2017

Patients who receive abaloparatide and switch to alendronate have a statistically significant reduction in fracture risk through 3.5 years, according to a new study…

Filed under:Biologics/DMARDsDrug Updates Tagged with:abaloparatidealendronateBiologics & Biosimilarsetanerceptetanercept-szzsFractureshiphip fracturehip fracture risk

Undetected Fractures Linked to Back Pain in Older Men

Shereen Lehman  |  September 22, 2017

(Reuters Health)—About three in five older men with tiny spinal fractures related to osteoporosis reported new or worsening back pain in a new study. Only about one-quarter of new vertebral fractures are diagnosed by a doctor, the study team writes in their September 7 online report in Journal of Bone and Mineral Research, though the…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Back painFracturesOsteoporosisundetected fracturesvertebral fracture

Alendronate Decreases Hip Fracture Risk in Older Patients Using Oral Prednisolone

Lara C. Pullen, PhD  |  August 21, 2017

New research found that older patients on prednisolone who are also treated with alendronate experience a significantly lower risk of hip fracture. Alendronate use was also associated with a lower risk of death…

Filed under:Conditions Tagged with:alendronateelderlyFractureship fracturehip fracture riskprednisolone

A New Approach to Fracture Prevention

Susan Bernstein  |  December 14, 2016

Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetingdraft clinical guidelinefracture risk factorsFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoid-Induced Osteoporosis Prevention and Treatment: An Updated ACR Clinical GuidelineGlucocorticoidsOsteoporosis

Denosumab Linked to Rebound-Associated Fractures in Nine Patients

Reuters Staff  |  October 21, 2016

NEW YORK (Reuters Health)—Patients can develop rebound-associated vertebral fractures after stopping denosumab, a new report of nine cases shows. All of the patients were considered to be at low risk of fracture, and the fractures occurred within nine to 16 months of their last injection, Dr. Olivier Lamy and colleagues from Lausanne University Hospital in Switzerland…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:bone mineral density (BMD)bone turnover rebound (BTR)denosumabFracturesOsteoporosisosteoporosis treatmentsvertebral fracture

Epilepsy Patients May Have Poor Bone Health, High Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2016

Some patients with epilepsy have a higher risk of fracture due to falls, and some studies have suggested that anti-epileptic drugs may also contribute to the fracture risk. In a recent review, researchers examined if there is a link between epilepsy and osteoporosis, making recommendations to aid future research…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:anti-epletic drugsbonebone mineral density (BMD)EpilepsyFracturesOsteoporosis

Mediterranean Diet Tied to Lower Hip Fracture Risk

Andrew M. Seaman  |  March 29, 2016

(Reuters Health)—Women who maintain an overall healthy diet may benefit from a slightly reduced risk of hip fractures later in life, according to a new U.S. study. Women who followed a Mediterranean-style diet were about three tenths of a percent less likely to break a hip over about 16 years, compared to women who didn’t…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:DieteatingFractureshiphip fracturehip fracture riskMediterranean dietOsteoporosis

The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2016

The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…

Filed under:Biologics/DMARDsDrug Updates Tagged with:American College of Rheumatology (ACR)BiosimilarsFDAFood and Drug AdministrationinfliximabromosozumabTofacitinibtofacitinib citrate

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences